Erin Wilson
Stock Analyst at Morgan Stanley
(1.80)
# 3,062
Out of 4,843 analysts
22
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $26 → $28 | $22.84 | +22.59% | 7 | May 13, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $183.05 | +299.89% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $137.70 | +179.59% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $141.02 | +87.92% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $297.05 | -30.99% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $130.99 | +90.85% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $13.52 | +181.07% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $20.66 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $403.75 | -15.54% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.58 | +3,317.72% | 4 | Nov 14, 2017 |
Rapid7
May 13, 2025
Maintains: Equal-Weight
Price Target: $26 → $28
Current: $22.84
Upside: +22.59%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $183.05
Upside: +299.89%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $137.70
Upside: +179.59%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $141.02
Upside: +87.92%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $297.05
Upside: -30.99%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $130.99
Upside: +90.85%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $13.52
Upside: +181.07%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $20.66
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $403.75
Upside: -15.54%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.58
Upside: +3,317.72%